RxDoctor Payments DataLook up a doctor →

Sreedhar Mandayam, MD

Nephrology · Houston, TXNPI 1225051048

Payments from drug & device makers

$6,970,919in general payments, 2019–2025

Across 2,776 payments — averaging $2511.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$1.7M
  • Vertex$1.3M
  • Pfizer$776K
  • Astrazeneca UK Limited$433K
  • Sanofi US Services Inc.$411K
  • AstraZeneca$279K
  • plus $2.1M from 54 others
$2,042in research payments, 2019–2025

Across 6 payments — averaging $340.36 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Novo Nordisk AS$1K
  • Pfizer$940

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Novartis91$1,680,937
Vertex20$1,328,268
Pfizer97$775,995
Astrazeneca UK Limited7$433,258
Sanofi US Services Inc.35$410,914
AstraZeneca(2 entities)114$278,613
Amgen(2 entities)103$264,886
Novo Nordisk AS885$254,220
Calliditas Therapeutics US Inc.263$244,030
Travere Therapeutics, Inc.461$229,456
Genentech, Inc.36$148,415
Otsuka Pharmaceutical Co., Ltd.25$124,468
Otsuka America Pharmaceutical, Inc.97$99,497
Mallinckrodt Enterprises LLC95$84,928
Bayer84$84,381
Akebia Therapeutics Inc12$78,523
Hoffmann-la Roche Limited38$64,448
Otsuka Pharmaceutical Development & Commercialization, Inc.26$56,535
Sanofi39$53,899
GSK26$34,546
Takeda Pharmaceuticals U.S.A., Inc.5$33,953
Beigene, Ltd.1$30,287
Beigene USA, Inc.17$28,569
Johnson & Johnson15$23,214
Beone Medicines USA, Inc.3$21,046
Mallinckrodt Hospital Products Inc.27$20,959
Kyowa Kirin, Inc.19$17,825
Alnylam Pharmaceuticals Inc.1$14,063
Janssen Research & Development, LLC4$13,633
AMAG Pharmaceuticals, Inc.18$12,670
Biogen2$11,359
Boehringer Ingelheim1$2,155
Vifor Pharma, Inc.19$1,946
Boehringer Ingelheim International GmbH3$1,805
Merck9$1,395
Roche Products Limited3$1,308
Nxstage Medical, Inc.9$969
Aurinia Pharma U.S., Inc.8$638
Apellis Pharmaceuticals, Inc.4$347
Baxter Healthcare5$317
Novo Nordisk5$296
OPKO Pharmaceuticals, LLC7$254
Fresenius USA Marketing, Inc.7$227
Ardelyx, Inc.4$200
BTG International Inc.5$196
Bard Peripheral Vascular, Inc.3$143
Lilly USA, LLC2$135
Pharming Healthcare, Inc.1$127
Idorsia Pharmaceuticals US Inc1$120
Rhythm Pharmaceuticals, Inc.1$112
ANI Pharmaceuticals, Inc.2$100
Acacia Pharma Inc1$63
Kaneka Medical America LLC1$57
Abbott3$54
Angiodynamics, Inc.1$49
AbbVie1$27
EMD Serono, Inc.1$27
B. Braun Medical Inc.1$23
Sanofi-aventis U.S. LLC1$18
Daiichi Sankyo Inc.1$17

How this compares

$6,970,919 in reported general payments places this provider in the 95th percentile of 1,070 nephrology providers in Texas.

See all nephrology providers in Texas →

Medicare billing

Part B allowed, 2024
$128,348
Medicare patients
345
Services billed
925

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other nephrology in Houston

See the full list for Texas →

Where these figures come from

Is this you, or does something look wrong? →